Everest Group Life Sciences Digital Services Specialists PEAK Matrix® Assessment 2024

It is widely believed that machine learning and data mining are right on the cusp of becoming among the most important breakthroughs that the healthcare industry has seen in years. While applications of these techniques have already occurred elsewhere in the pharma sector, wide-spread applications in pharmaceutical commercial analytics have come more recently. Pharma companies are now looking to ...

Access to Healthcare Practitioners (HCPs) continues to be restricted in this ever-evolving healthcare ecosystem. Contact with stakeholders is typically limited due to stringent anti-rep policies and their organization’s rules and guidelines. This calls for new ways to reach these stakeholders and the evolution of pharmaceutical call planning. This white paper explores the factors used to develop ...

The concept of “all marketing is local” in the pharma environment is more valid today than ever before. We see tremendous variations in salient factors that would affect commercial outcomes from sales and marketing promotion-response and optimization modeling at a subnational level. Data has become more available at the physician, patient, and healthcare system levels allowing for more precise ...

No pharmaceutical topic causes as much passionate difference of opinions between industry and medical community representatives as the practice of direct-to-consumer advertising (DTCA), with the likely exception being drug pricing. Despite criticisms and the heated debate on the appropriateness of this channel, DTCA spending continues to grow. The drug industry spent approximately $5.6 billion on ...

The pharmaceutical industry continues to undergo tremendous changes. The questions for executives are how do these changes affect the direction of investments in new decision science technologies and whether there should be focus on certain areas of expertise that are felt to offer a competitive advantage for the company? These choices in the direction of investments are embodied in the title of ...

Effective roster management has long been an overlooked topic in Pharma commercial operations. At any point in time, it is critical for the Sales Operations business processes to have access to the latest and distinct set of sales personnel that will need to be accounted for. All functions of commercial operations including sales force sizing, alignment management, call planning, and incentive ...

One of the more vexing and troubling public health policy issue that has plagued the US pharma industry, yet receiving less deserving public news coverage than other industry stories, has been the existence of chronic drug shortages since the turn of the 21st century. A drug shortage is defined in which the “total supply of all clinically interchangeable versions of an FDA-regulated drug is ...

The healthcare landscape has changed. The traditional way of aligning sales teams is no longer effective. To remain competitive, organizations must deploy sophisticated go-to-market models where talent structures are aligned to engage new stakeholders across multiple channels, regions, specialities and organization size. The impact of inefficient territory alignment is significant: compared to ...

The entry of biosimilars into the US pharmaceutical market is a very recent phenomenon beginning in 2015 with the launch of Zarxio. Three biosimilars were added in 2016, with more predicted in 2017 at the time of this publication. Europe has experienced biosimilars since 2006, and thus can serve as an initial benchmark for insights through empirical studies that may be drawn for predicted effects ...